FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

			 •••
Washington	DC2	0549	

Washington, D.C. 20049	OMB APPROVAL			
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	OMB Number:	3235-0287		

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OIVIB APPROVAL										
OMB Number: 3235-028										
Estimated average burden										
hours per response:	0.5									

	e conditions of ee Instruction 1																		
Name and Address of Reporting Person*  Lee Kevin					2. Issuer Name <b>and</b> Ticker or Trading Symbol BICYCLE THERAPEUTICS PLC BCYC							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
			]]									1	Direc			10% Ov			
(Last)	(Last) (First) (Middle)					-							_	1	Officer (give title below)			Other (specify below)	
C/O BICYCLE THERAPEUTICS PLC			3. Date of Earliest Transaction (Month/Day/Year) 10/03/2024								CHIE	F EXECU	TIV	E OFFICI	ER				
BLOCKS A & B, PORTWAY BUILDING			10/03/2021																
(Stroot)					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) CAMBR	IDGE X	C	CB21 6	6GS										Form filed by One Reporting Person					
														Form filed by More than One Reporting Person					
(City)	(St	ate) (Z	Zip)																
		Table	I - No	on-Deriva	tive S	Secui	rities	Acc	quired	l, Dis	posed of	, or E	Benefic	ially	Own	ed			
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/				.	Execution Date			3. Transaction Code (Instr. 8)		Acquired (A) or f (D) (Instr. 3, 4 a		nd 5) Securi Benefi Owned		ities Folicially (I)		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership		
						Code	v	Amount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)			
Ordinary Shares 10/03/20					024				S <sup>(1)</sup>		3,212	D	\$22.2	26(2)	380,864		D		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execution Date, irity or Exercise (Month/Day/Year) if any			Transaction of Code (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Date Exerci	isable	Expiration Date	Title	Amount or Number of Shares						

## **Explanation of Responses:**

- 1. Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$21.91 to \$22.56 inclusive. The Reporting Person undertakes to 2. The price reported in Column 4 is a weighted average price. I nese shares were sold in multiple transactions at prices ranging from \$21.91 to \$22.56 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

/s/ Jason Minio, Attorney-in-

**Fact** 

\*\* Signature of Reporting Person Date

10/04/2024

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.